Aventis/Genta Genasense Melanoma NDA Expected To Go Before FDA Oncology Committee In May
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has granted priority review to the NDA for oblimersen sodium for treatment in combination with chemotherapy. The user fee action date is June 8.